<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216410</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00012142</org_study_id>
    <secondary_id>Duke-12142</secondary_id>
    <nct_id>NCT01216410</nct_id>
  </id_info>
  <brief_title>Prevention of Intraoperative Nausea and Vomiting During Cesarean Section</brief_title>
  <official_title>The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the incidence of intraoperative nausea and vomiting under spinal
      anesthesia using a phenylephrine infusion with and without prophylactic antiemetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative Nausea and Vomiting</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Comparison of intraoperative nausea and vomiting between the 3 groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and Vomiting (PONV)</measure>
    <time_frame>0-2h, 2-6h, 6-24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus</measure>
    <time_frame>0-24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>24 h</time_frame>
    <description>1=very satisfied, 2=somewhat satisfied, 3= neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5= very dissatisfied. Number of very satisfied subjects posted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Hemodynamics</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>The number of patients with systolic blood pressure decrease to less than 20 % of baseline intraoperatively</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Cesarean Delivery</condition>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylaxis with metoclopramide and phenylephrine infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prophylactic phenylephrine infusion and placebo antiemetics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion</description>
    <arm_group_label>Metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine infusion</intervention_name>
    <description>Prophylactic phenylephrine infusion after spinal and placebo antiemetics</description>
    <arm_group_label>Phenylephrine infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Group</intervention_name>
    <description>Metoclopramide and ondansetron prophylaxis with phenylephrine infusion</description>
    <arm_group_label>Combination Group</arm_group_label>
    <other_name>Metoclopramide and ondansetron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking ASA I-II non-laboring women with single gestations â‰¥36 weeks

          -  Scheduled or unscheduled cesarean delivery under spinal anesthesia

          -  Height: 5 feet-5 feet 11 in.

        Exclusion Criteria:

          -  Laboring women needing an emergency cesarean delivery

               -  Subjects less than 18 years of age

               -  Receipt of a drug with antiemetic properties in the 24 hours prior to cesarean
                  section

               -  Allergy to ondansetron, or metoclopramide

               -  Severe hypertensive disease of pregnancy defined as systolic blood pressure
                  (SBP)&gt;160mmHg, diastolic blood pressure (DBP)&gt;110mmHg requiring antihypertensive
                  treatment or associated with significant proteinuria.

               -  Severe Cardiac disease in pregnancy with marked functional limitations

               -  Diabetes type I

               -  Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants

               -  Morbid obesity (body mass index (BMI)&gt;45)

               -  Inclusion in another anesthetic study involving drug administration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <results_first_submitted>November 19, 2012</results_first_submitted>
  <results_first_submitted_qc>February 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2013</results_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>December 2008-January 2011, University Medical Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination Group</title>
          <description>Metoclopramide and Ondansetron prophylaxis
Combination Group : Metoclopramide and ondansetron prophylaxis</description>
        </group>
        <group group_id="P2">
          <title>Metoclopramide</title>
          <description>Metoclopramide : Prophylactic Metoclopramide 10 mg given before spinal</description>
        </group>
        <group group_id="P3">
          <title>Phenylephrine Infusion</title>
          <description>Prophylactic phenylephrine infusion and placebo antiemetics
Phenylephrine infusion : Prophylactic phenylephrine infusion after spinal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination Group</title>
          <description>Metoclopramide and Ondansetron prophylaxis
Combination Group : Metoclopramide and ondansetron prophylaxis</description>
        </group>
        <group group_id="B2">
          <title>Metoclopramide</title>
          <description>Metoclopramide : Prophylactic Metoclopramide 10 mg given before spinal</description>
        </group>
        <group group_id="B3">
          <title>Phenylephrine Infusion</title>
          <description>Prophylactic phenylephrine infusion and placebo antiemetics
Phenylephrine infusion : Prophylactic phenylephrine infusion after spinal</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="103"/>
            <count group_id="B4" value="306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="6"/>
                    <measurement group_id="B2" value="31" spread="5"/>
                    <measurement group_id="B3" value="32" spread="6"/>
                    <measurement group_id="B4" value="31" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Nausea and Vomiting</title>
        <description>Comparison of intraoperative nausea and vomiting between the 3 groups.</description>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Group</title>
            <description>Metoclopramide and Ondansetron prophylaxis
Combination Group : Metoclopramide and ondansetron prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>Metoclopramide : Prophylactic Metoclopramide 10 mg given before spinal</description>
          </group>
          <group group_id="O3">
            <title>Phenylephrine Infusion</title>
            <description>Prophylactic phenylephrine infusion and placebo antiemetics
Phenylephrine infusion : Prophylactic phenylephrine infusion after spinal</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Nausea and Vomiting</title>
          <description>Comparison of intraoperative nausea and vomiting between the 3 groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Nausea and Vomiting (PONV)</title>
        <time_frame>0-2h, 2-6h, 6-24h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Group</title>
            <description>Metoclopramide and Ondansetron prophylaxis
Combination Group : Metoclopramide and ondansetron prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>Metoclopramide : Prophylactic Metoclopramide 10 mg given before spinal</description>
          </group>
          <group group_id="O3">
            <title>Phenylephrine Infusion</title>
            <description>Prophylactic phenylephrine infusion and placebo antiemetics
Phenylephrine infusion : Prophylactic phenylephrine infusion after spinal</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Nausea and Vomiting (PONV)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-2 hrs PONV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-6 hrs PONV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-24 hrs PONV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pruritus</title>
        <time_frame>0-24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Group</title>
            <description>Metoclopramide and Ondansetron prophylaxis
Combination Group : Metoclopramide and ondansetron prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>Metoclopramide : Prophylactic Metoclopramide 10 mg given before spinal</description>
          </group>
          <group group_id="O3">
            <title>Phenylephrine Infusion</title>
            <description>Prophylactic phenylephrine infusion and placebo antiemetics
Phenylephrine infusion : Prophylactic phenylephrine infusion after spinal</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritus</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction</title>
        <description>1=very satisfied, 2=somewhat satisfied, 3= neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5= very dissatisfied. Number of very satisfied subjects posted.</description>
        <time_frame>24 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Group</title>
            <description>Metoclopramide and Ondansetron prophylaxis
Combination Group : Metoclopramide and ondansetron prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>Metoclopramide : Prophylactic Metoclopramide 10 mg given before spinal</description>
          </group>
          <group group_id="O3">
            <title>Phenylephrine Infusion</title>
            <description>Prophylactic phenylephrine infusion and placebo antiemetics
Phenylephrine infusion : Prophylactic phenylephrine infusion after spinal</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction</title>
          <description>1=very satisfied, 2=somewhat satisfied, 3= neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5= very dissatisfied. Number of very satisfied subjects posted.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Hemodynamics</title>
        <description>The number of patients with systolic blood pressure decrease to less than 20 % of baseline intraoperatively</description>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Group</title>
            <description>Metoclopramide and Ondansetron prophylaxis
Combination Group : Metoclopramide and ondansetron prophylaxis</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>Metoclopramide : Prophylactic Metoclopramide 10 mg given before spinal</description>
          </group>
          <group group_id="O3">
            <title>Phenylephrine Infusion</title>
            <description>Prophylactic phenylephrine infusion and placebo antiemetics
Phenylephrine infusion : Prophylactic phenylephrine infusion after spinal</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Hemodynamics</title>
          <description>The number of patients with systolic blood pressure decrease to less than 20 % of baseline intraoperatively</description>
          <units>participants with SBP&lt; 20 % baseline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combination Group</title>
          <description>Metoclopramide and Ondansetron prophylaxis
Combination Group : Metoclopramide and ondansetron prophylaxis</description>
        </group>
        <group group_id="E2">
          <title>Metoclopramide</title>
          <description>Metoclopramide : Prophylactic Metoclopramide 10 mg given before spinal</description>
        </group>
        <group group_id="E3">
          <title>Phenylephrine Infusion</title>
          <description>Prophylactic phenylephrine infusion and placebo antiemetics
Phenylephrine infusion : Prophylactic phenylephrine infusion after spinal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ashraf Habib</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919 668 6266</phone>
      <email>habib001@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

